Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer

Guia Vannucchi1, Simone De Leo2, Michela Perrino2, Stefania Rossi3, Delfina Tosi4, Valentina Cirello5, Carla Colombo2, Gaetano Bulfamante3,4, Leonardo Vicentini6 and Laura Fugazzola1,5

1Endocrine Unit, Padiglione Granelli, Fondazione IRCCS Ca’ Granda, Via F. Sforza, 35, 20122 Milan, Italy, 2Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, 3Division of Pathology, San Paolo Hospital, Milan, Italy, Departments of 4Health Sciences and 5Pathophysiology and Transplantation, University of Milan, Milan, Italy and 6Endocrine Surgery Unit, Fondazione IRCCS Ca’ Granda, Milan, Italy

Abstract

Background: Thyroid cancer is highly prevalent in women during the fertile age, which suggests a possible impact of hormonal and reproductive factors.

Methods: We studied the expression of estrogen receptor α (ERα or ESR1) and progesterone receptor (PR or PGR) in 182 female and male patients with papillary thyroid cancer and correlated it to clinical and molecular features.

Results: ERα and PR expression was found in 66.5 and 75.8% of patients respectively and was significantly correlated with larger tumor size and with a non-incidental diagnosis. Moreover, a trend toward a higher prevalence of local metastases was observed in ER- and PR-expressing tumors, which possibly indicates a more aggressive behavior. Interestingly, the occurrence of the ‘receptor conversion’ phenomenon, which has already been reported to have a negative prognostic effect in breast cancer, was demonstrated for the first time in thyroid tumors. Indeed, almost all of the ERα-positive primary tumors analyzed had ERα-negative metastatic lymph nodes. At the genetic analyses, BRAFV600E mutation was detected in 23.2% of the tumors and had a higher prevalence in larger tumors and in those with a stronger ERα or PR staining.

Conclusions: The whole of the findings reported in the present study argue for an association between ERα and PR sex hormone receptor expression and a more aggressive presentation. Although no impact on outcome was found, the evaluation of ERα and PR receptor expression could add insights into the biological behavior of tumors and could modify the follow-up, particularly in fertile women affected with persistent disease.

Introduction

In more developed countries, thyroid cancer is the second most frequent malignancy in women during the fertile age (1), which suggests a possible impact of hormonal and reproductive factors. Consistently, in the past few decades, epidemiological and experimental findings have indicated a possible role of estrogens in the development and progression of differentiated thyroid tumors (2, 3). It is known that estrogens can regulate thyroid cell proliferation by binding to both estrogen receptors (ERs), ERα (ESR1) and ERβ (ESR2), and displaying different effects on cell survival and proliferation. In particular, a proliferative and anti-apoptotic effect and a role in metastatization have
been shown for ER\(\alpha\), whereas ER\(\beta\) has a differentiative and pro-apoptotic action (3, 4). Upon activation by estradiol (E\(2\)), ER translocates to the nucleus and activates gene transcription. In thyroid cancer cell lines, the proliferative effects of estrogen were found to be mediated through the regulation of genes involved in growth control, such as bcl-2, Bax, c-fos, E-cadherin, and vimentin (4, 5, 6). Alternatively, E\(2\) activation leads to a 'non-genomic' action by ER, which includes a rapid activation of the intracellular ERK-1/2 and PI3K/Akt signaling pathways (7).

Several studies on ER expression have been performed in both normal and neoplastic thyroid tissues with extremely variable results, mostly because of the poor reproducibility of the methods used (revised in (8)). Nevertheless, strong evidence exists that ER\(\alpha\) expression is significantly greater in patients with various types of thyroid neoplasms than it is in normal controls, whereas ER\(\beta\) is significantly less expressed in tumors than it is in normal thyroid tissues (9, 10). The increased expression of ER\(\alpha\) in thyroid cancer might influence the development and progression of the tumor, particularly during pharmacological and physiological conditions characterized by high circulating estrogen levels. Indeed, in a recent case–control study on a large population, it was shown that the risk of thyroid cancer is significantly correlated with early menarche and higher number of pregnancies (11), and we and others have demonstrated that thyroid cancers diagnosed during pregnancy are associated with a poorer outcome (12, 13, 14). An increased risk of thyroid cancer has also been documented in women who have been treated with estrogen for gynecological reasons and in women who were taking oral contraceptive pills (15). Interestingly, estrogen metabolites and conjugates have been found to be significantly higher in women with well-differentiated thyroid cancer as compared to age-matched control women (16).

To define the possible role of estrogens in the development and progression of thyroid cancers, studies comparing the expression of ER in tumor tissues with the histopathological and clinical characteristics are warranted. To date, only two studies on T1 and T2 papillary thyroid cancers (PTCs) have shown a correlation between ER\(\alpha\)-positive and ER\(\beta\)-negative expression and worse histopathology data (17, 18). In terms of progesterone receptor (PR) concerns, only a few expression studies in thyroid tissues have been published (13, 19), and no data have yet been produced on the impact of ER\(\alpha\) and PR expression on the disease outcome in PTCs.

Thus, the aim of the present study was to investigate the expression of ER\(\alpha\) and PR in a large series of PTCs using immunohistochemistry and to correlate that expression to the clinical and molecular features and to the disease outcome.

**Patients and methods**

**Patients**

One hundred eighty-two consecutive patients (142 females, 40 males, mean age 47.9, range 14–83) with available paraffin-embedded thyroid tumor tissue blocks were studied. In seven of them, neck metastatic lymph node tissue samples were also collected. Eighty-seven female patients (61%) were diagnosed before menopause. All of the patients underwent total thyroidectomy that, for those with a preoperative diagnosis of malignancy, was associated with a pretracheal and paratracheal lymphadenectomy (levels VI–VII), and all have been treated and followed up in our university hospital. Patients with clinical and/or cytological suspicion of neck metastases were also submitted to mono- or bilateral laterocervical lymph node dissection. After surgery, patients were maintained on thyrotropin (TSH)-suppressive levothyroxine (L-T\(4\)) treatment unless disease remission was documented, and they were then shifted to lower doses, with an aim of reaching TSH levels between 0.5 and 1.0 mU/l. The approval of the ethical committee was obtained for the present retrospective observational study.

**Tumor classification and outcome definition**

Tumors were classified and staged according to the thyroid malignancy World Health Organization classification AJCC Cancer Staging Manual, 7th edn (20). Only tumors with an extrathyroidal invasion (i.e., invasion of the thyroid capsule and/or lymph nodal or distant metastases) or with a diameter >2 cm were submitted to radioiodine residue ablation, according to current guidelines (21). The criteria used to identify remission or persistent/recurrent disease were based on the European and American guidelines for the management of differentiated thyroid cancer (21, 22) and have been previously reported in detail (23).

**BRAFV\(600E\) mutation analysis**

Neoplastic cells were obtained by laser microdissection from the tumor tissue of 151 patients with a diagnosis of PTC. DNA was extracted from microdissected tissues, and BRAFV\(600E\) mutation was analyzed by PCR amplification and direct sequencing, as previously described (24).
Immunohistochemical analysis of ERα and PR in tumor tissues

Formalin-fixed paraffin-embedded tissue sections (4 μm) were dewaxed in xylene and rehydrated in graded ethanol solutions. Antigen retrieval was obtained by incubating tissue sections at 100°C for 30 min in EDTA 0.05 M pH 8.0. Endogenous peroxidase block was performed by immersion of the slides in 3% hydrogen peroxide. Sections were incubated for 30 min with the primary MAB ERα (clone 1D5, diluted 1:200) and PgR (clone 636, diluted 1:100), supported by Dako (Carpinteria, CA, USA). The reaction was detected by a Novolink Max polymer detection system (Novocastra Laboratories Ltd, Leica Microsystems, Nußloch, Germany), following manufacturer’s instructions, using diaminobenzidine (DAB) as chromogen and incubating for 8 min at RT. One slide that included negative controls lacking the primary antibody and incubating for 8 min at RT. One slide that included negative controls lacking the primary antibody was immunostained in the same batch. The sections were counterstained with hematoxylin and examined after dehydration and mounting. Scoring of immunoreactivity of ERα and PR expression was performed on a high-power field (X40) using a standard light microscope. Immunohistochemistry results were classified as absent expression, weak positivity when <30% of the cells were stained, and strong positivity when ≥30% cells were stained.

Statistical analysis

Relations between discrete variables were evaluated by means of a χ² test or t-test, as appropriate. Statistical significance was defined as P<0.05. All statistical analyses were performed using SPSS version 8.0 statistical package for Windows and MedCalc Software version 12.5.00 for Windows.

Results

Clinical and histopathological features

The clinical and histopathological characteristics of the enrolled patients are summarized in Table 1. In particular, the mean age at diagnosis was 47.9±14.5 years and the tumor size was 15.6±11.3 mm. About half of the patients (53.8%) had a multifocal tumor, and the classical variant of papillary cancer was the most frequent histotype (80.9%). An extrathyroidal extension was recorded in 66/182 (36.2%) cases, and lymph node metastases were found at diagnosis in 63 patients (34.6%). After a mean±s.d. follow-up of 73±37.5 months, the disease was persistent or recurrent in 27/163 (16.6%) patients. One female patient with persistent disease became pregnant, although contraindicated, and was followed during gestation. During pregnancy, her TSH levels were maintained and well suppressed (i.e., <0.01 mU/l). T4 was titrated according to the TSH levels, and minor dose adjustments were required but were limited to the first two trimesters of pregnancy. She showed a progressive increase in serum thyroglobulin (Tg) levels, from pre-pregnancy values of 33–73.2, 108, and 119 μg/l in the first, second, and third trimester respectively. Her serum Tg levels decreased to 60 μg/l 1 month after delivery (Fig. 1).

Immunohistochemical analysis of ERα and PR in tumor tissues

ERα expression was found in 121/182 cases (66.5%), whereas PR expression was found in 138/182 cases (75.8%), and there were no significant differences among sexes either for ERα or for PR. The staining was weak in 77/90 ERα-positive female and 26/31 ERα-positive male cases as well as in 70/109 PR-positive female and 15/29 PR-positive male cases, and it was strong in the remaining positive patients (data not shown). ERα and PR expression significantly correlated with tumor size, either in terms of the dimensions as a continuous variable (P=0.002 and P<0.0001 by t-test) or when dividing the tumors into

Table 1 Clinical, histopathological, and molecular characteristics of patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Whole group (n=182)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at diagnosis (mean±s.d.)</td>
<td>47.9±14.5</td>
</tr>
<tr>
<td>Incidental tumors (n (%))</td>
<td>73 (40.1)</td>
</tr>
<tr>
<td>Tumor size (mm, mean±s.d.)</td>
<td>15.6±11.3</td>
</tr>
<tr>
<td>Tumor extension (n (%))</td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>105 (57.7)</td>
</tr>
<tr>
<td>T2</td>
<td>11 (6)</td>
</tr>
<tr>
<td>T3</td>
<td>63 (34.6)</td>
</tr>
<tr>
<td>T4</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>Multifocality</td>
<td>98 (53.8)</td>
</tr>
<tr>
<td>Histological variants (n (%))</td>
<td></td>
</tr>
<tr>
<td>Classical papillary</td>
<td>152 (80.9)</td>
</tr>
<tr>
<td>Papillary-follicular variant</td>
<td>26 (13.8)</td>
</tr>
<tr>
<td>Papillary sclerosant variant</td>
<td>6 (3.2)</td>
</tr>
<tr>
<td>Oncocytic variant</td>
<td>4 (2.1)</td>
</tr>
<tr>
<td>Autoimmunity</td>
<td>32/133 (24.1)</td>
</tr>
<tr>
<td>Lymph-node metastases (n (%))</td>
<td>63 (34.6)</td>
</tr>
<tr>
<td>Stage (n (%))</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>129 (70.9)</td>
</tr>
<tr>
<td>II</td>
<td>4 (2.2)</td>
</tr>
<tr>
<td>III</td>
<td>36 (19.8)</td>
</tr>
<tr>
<td>IV</td>
<td>13 (7.1)</td>
</tr>
<tr>
<td>BRAF (V600E) mutation (n (%))</td>
<td>35/151 (23.2)</td>
</tr>
<tr>
<td>Outcome (persistence) (n (%))</td>
<td>27/163 (16.6)</td>
</tr>
</tbody>
</table>
trois sous-groupes (≤1, 1–2, ou >2 cm, \(P=0.006\) et \(P=0.002\) par test \(\chi^2\)) (Fig. 2A). De plus, l’expression d’ER\(\alpha\) et PR était plus fréquente dans les tumeurs cliniquement évidentes par rapport aux cas incidents (\(P=0.0001\) pour les deux) (Fig. 2B). L’analyse de régression logistique qui a été faite en utilisant les paramètres qui étaient significativement associés à l’expression d’ER\(\alpha\) et PR pendant le test univarié comme variables d’entrée a confirmé que l’expression d’ER\(\alpha\) et PR sont indépendamment associées à la taille tumorale plus grande (ER\(\alpha\): \(P=0.027\); PR: \(P=0.05\)) ou à l’incidence diagnostique (ER\(\alpha\): \(P=0.004\); PR: \(P=0.0002\)).

Une tendance non statistiquement significative a été observée vers une plus grande prévalence de métastases locales dans les tumeurs ER\(\alpha\)-et PR-exprimant. (Fig. 3A). En revanche, nous n’avons pas observé d’extension extrathyroidale significative avec l’expression d’ER\(\alpha\) et PR (Fig. 3B et C). Finalement, la prévalence de l’expression d’ER\(\alpha\) et PR n’a pas significativement changé pendant la période pré- et post-ménopausale (\(P=0.16\) et \(P=0.54\) respectivement) (data not shown).

En sept cas, nous avons eu l’opportunité de comparer l’expression d’ER\(\alpha\) et PR entre le tissu primaire et le tissu ganglionnaire cervical métastatique. Dans cinq patients qui avaient une expression positive d’ER\(\alpha\) dans le tissu primaire, l’ER\(\alpha\) n’était pas exprimé dans les tissus métastatiques, alors qu’un patient avait une expression négative d’ER\(\alpha\) dans les deux tissus primaires et métastatiques, et un autre patient était négatif en l’expression d’ER\(\alpha\) dans le tissu primaire.

**BRAF\(^{V600E}\)** molecular analysis

La mutation de BRAF\(^{V600E}\) a été détectée chez 35/151 (23.2%) tissus. Notamment, la prévalence de la mutation BRAF\(^{V600E}\) variait significativement lorsqu’on divisait les tumeurs en fonction de leurs diamètres: ≤1 cm: 9.5%, 1–2 cm: 29.3%, >2 cm: 36.4% (\(P=0.004\)). La prévalence BRAF\(^{V600E}\) était similaire parmi les patients en rémission ou avec une survenue/relapse (25.2 vs 20.8%, \(P=0.85\)) (data not shown). Les cas ER\(\alpha\)- et PR-positifs ont tendance à porter, bien que non statistiquement significative, la mutation BRAF\(^{V600E}\) plus fréquemment que les cas négatifs. Intéressant, lorsque les patients étaient divisés suivant le degré de coloration, une tendance a montré une corrélation entre l’intensité de coloration des deux récepteurs et la mutation BRAF\(^{V600E}\), qui était statistiquement significative pour l’expression PR (\(P=0.03\)) (Fig. 5).

**Figure 1**

Serum thyroglobulin (Tg) levels in a female patient with papillary thyroid cancer (PTC) during the three trimesters of pregnancy and after delivery. Exemplificative hCG and estrogen trends during the normal singleton pregnancy are also shown.
Discussion

In the present study, ERα and PR were found to be frequently expressed in differentiated thyroid cancers (66 and 76% respectively). This prevalence is higher than that reported in some previous studies (13, 17, 25, 26), although the available data are scanty, controversial, and were obtained in more limited series. Indeed, some authors found an up-regulation of ERα in PTCs when using immunohistochemistry (19, 27, 28), whereas others did not find any difference in ERα expression in thyroid tumors with respect to normal tissues, or they observed a lack of ER expression in thyroid neoplasms (8, 25, 26). Most of these discrepancies are likely a result of the methodologies used. On the other hand, recently published data have clearly demonstrated, by means of different approaches (such as laser-capture microdissection, magnetic immunoprecipitation, real-time PCR, and western blot), the expression of ERα in thyroid tumor tissues but not in normal thyroid tissues (9). In the present series, tumors with a positive ER and PR staining were significantly and independently associated with a larger tumor size and were more frequently...

<table>
<thead>
<tr>
<th>A</th>
<th>ERα tumor</th>
<th>ERα LN</th>
<th>PR tumor</th>
<th>PR LN</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>#2</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>#3</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>#4</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>#5</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>#6</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>#7</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Figure 3

(A) ERα and PR expression and lymph node metastases at diagnosis. (B) ERα and PR expression and extrathyroidal invasion. (C) ERα and PR expression and outcome.

Figure 4

(A) The phenomenon of ‘receptor conversion’ between the primary differentiated thyroid tumor and the metastatic lesion in seven cases of primary papillary thyroid cancer and lymph node metastases (LN). (B) ERα-positive staining in a thyroid tumor tissue. (C) ERα-negative staining in a neck lymph node metastasis.
non-incidental at diagnosis, which is consistent with previous data obtained in T1 and T2 thyroid tumors (17, 18). Moreover, a trend toward a higher prevalence of local metastases was observed in ER- and PR-expressing tumors, which possibly indicates a more aggressive behavior. Despite this worse presentation, no impact on outcome was recorded, likely as a consequence of the highly effective diagnostic and therapeutic tools available for this neoplasm and its recognized benign course. The comparative study of primary tumors and metastatic lymph nodes allowed us to demonstrate for the first time in thyroid tumors the occurrence of the ‘receptor conversion’ phenomenon for ERα (29). Indeed, almost all of the ERα-positive primary tumors analyzed had ERα-negative metastatic lymph nodes. On the contrary, the same pattern of PR expression was found in primary tumors and lymph nodal metastases. Although they are preliminary, these data are consistent with those reported in breast cancer for both ER and PR. In particular, several studies have shown that the receptor status of breast metastases may differ from that of the primary tumor, with the primary tumor being positive and metastases being negative in most cases (30, 31). This finding may be explained by either the clonal selection of less-differentiated receptor negative cells during the metastatic process or the occurrence of a genetic drift during tumor progression (32). Nevertheless, the definite role of receptor conversion in thyroid cancer remains to be clarified, seeing as the data reported here are novel and preliminary. Still, considering that receptor conversion in breast cancer has been associated with a negative prognostic effect, more studies on this topic would be of interest (33).

The present study is the first to compare ERα and PR expression not only with the histopathological data but also with outcome and with the molecular analysis of \( \text{BRAF}^{V600E} \). This genetic alteration was significantly more prevalent in larger tumors, although there was no correlation with outcome, as has been previously reported for our population (34). Interestingly, \( \text{BRAF}^{V600E} \) mutation was found to be more common in tumors that positively stained for ERα and PR, although the relatively limited number of cases did not allow it to reach statistical significance. This finding is of particular interest, because it is known that in benign and malignant thyroid cells, E2 can stimulate the Ras/Raf/MAP kinase signaling pathway via its membrane-bound receptor (35). Thus, an additive action on this pathway, which is critical for the proliferation and propagation of thyroid cancer, could be hypothesized for tumors that are harboring both the ER expression and the \( \text{BRAF}^{V600E} \) mutation.

The whole of the findings reported in the present study argue for an association between sex hormone receptor expression and a more aggressive presentation. It is possible to speculate that, at least in females, this finding could also result from the action of sex hormones on ERα and PR-expressing tumors, as has been suggested in previous studies that reported a worse outcome for thyroid cancer when it was diagnosed during pregnancy (12, 13, 14). Accordingly, it is well documented in benign and malignant thyroid carcinoma cells that E2 stimulates growth and amplifies its growth-promoting effect by the up-regulation of ERα (2, 6). In this context, we had the opportunity to follow up a woman with persistent PTC who showed a progressive increase of serum Tg levels during pregnancy, with a maximum value just before delivery and a progressive reduction in the postpartum period. The possible contribution of the placenta to the Tg elevation seems to be excluded by data that demonstrate the absence of either Tg mRNA or Tg as a protein in the placenta, decidua, or ovaries in any stage of pregnancy (36). On the other hand, the Tg rise could be correlated to the increase of chorionic gonadotropin (CG) that occurs during the first trimester of pregnancy, which represents an important growth factor for thyrocytes. Nevertheless, in our patient, the most relevant increase of serum Tg occurred in the second and third trimester of pregnancy, paralleling the estrogen increase. Thus, we are prompted to speculate an estrogen rather than a CG effect.

In conclusion, the present study confirmed that the expression of ERα and PR is frequent in thyroid tumor
tissues, and it is significantly associated with larger tumor size and, consistently, with a non-incidental diagnosis. Moreover, a trend toward a higher prevalence of local metastases and a higher prevalence of BRAF^{V600E} mutations were observed in ER- and PR-expressing tumors, which possibly indicates a more aggressive behavior. Although no impact on the outcome of the disease was observed, the evaluation of sex hormone receptors could add insights into the biological behavior of tumors, and it could modify follow-up, particularly in fertile women affected with persistent disease. In addition, the phenomenon of receptor conversion, which has been reported here in thyroid tumors for the first time, could represent another issue to consider in follow-up, and further studies are needed in order to understand its effect on thyroid tumor prognosis. Finally, the finding of a strong expression of ER in some thyroid tumors suggests the need to evaluate the possible usefulness of an anti-estrogen therapy in selected cases to attenuate the growth-promoting effects of E2.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References
21 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McVey B, Pacini F et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.


Received 15 January 2015
Revised version received 1 April 2015
Accepted 10 April 2015